DLDamien Levard

Damien Levard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Damien Levard has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Denis Vivien

    Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Cyceron

    6 shared publications
  • Marina Rubio

    Normandie University, UNICAEN, Université Caen Normandie, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institut Blood and Brain @ Caen-Normandie (BB@C), Caen, France

    6 shared publications
  • Antoine Drieu

    Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France

    3 shared publications
  • Denis Vivien

    Normandie Univ, UNICAEN, INSERM, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders, Institut Blood and Brain @ Caen-Normandie, Cyceron, France

    3 shared publications
  • Carine Ali

    Normandie Univ, UNICAEN, INSERM, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders, Institut Blood and Brain @ Caen-Normandie, Cyceron, Caen, France

    2 shared publications
  • Eloïse Lemarchand

    School of Biological Sciences 1 Division of Neuroscience Faculty of Biology, Medicine and Health AV Hill Building, Manchester M13 9PT

    2 shared publications

Latest Publications

  • Open Access

    Microglia and border-associated macrophages play opposite roles in cerebrovascular and leukocyte responses under systemic inflammation in male mice

    by Ana Rita Brás, Nikolett Lénárt, Damien Levard, Martina Glavan, Ákos Menyhárt, Csaba Cserép, Balázs Pósfai, Eszter Császár, Sai K. Reddy Samawar, Clare Pridans, et al.

    Microglia closely associate with the vasculature, but their roles in leukocyte trafficking and cerebral blood flow (CBF) during systemic inflammation are unclear. We show that sustained systemic inflammation leads to altered microglia-vascular interactions, leukocyte recruitment to cerebral blood vessels and reduced hypercapnia-induced vasodilation. We find that microglia and border-associated macrophages (BAMs) play distinct roles in these processes: while BAM depletion with clodronate increases leukocyte recruitment, microglia/BAM depletion with PLX5622 and the absence of microglia, but not BAMs in CSF1RΔFIRE/ΔFIRE mice, result in markedly reduced leukocyte recruitment. Supporting this, conditional microglial IL-1 deletion inhibits leukocyte recruitment. Unlike BAM depletion, the absence of microglia impairs hypercapnia-induced vasodilation, while in vivo two-photon imaging reveals microglial IL-1α-dependent interactions between leukocytes and penetrating arteries. Accordingly, reduced hypercapnia-induced vasodilation involves endothelial IL-1R1 and microglial IL-1α. Thus, distinct brain macrophage populations exert opposite effects on leukocyte recruitment and CBF through IL-1 dependent mechanisms in given vascular beds in male mice.

  • Les macrophages périvasculaires cérébraux comme modulateurs de la réponse inflammatoire post-ischémique

    by Damien Levard

    L'AVC ischémique est l'une des principales causes de décès et d'invalidité permanente dans le monde. Les processus inflammatoires induits par l'AVC ont été proposés comme des contributeurs clés de la physiopathologie de l'AVC ischémique. Alors que le rôle de la microglie dans l'AVC ischémique a été largement étudié, celles des macrophages associés aux bordures du SNC (BAMs) restent largement inconnues. Notre hypothèse, basée sur les études décrites précédemment et sur la localisation privilégiée des BAMs à l’interface entre le compartiment vasculaire et le parenchyme cérébral, était que les BAMs pouvaient jouer un rôle majeur dans la réponse inflammatoire déclenchée par l’AVC, via la médiation du recrutement et l’infiltration des leucocytes. De plus, sur la base d’études précédentes, nous avons fait l’hypothèse que les BAMs pourraient moduler les réponses inflammatoires induites par l'AVC de manière différente en fonction de l'état inflammatoire basal du cerveau, en particulier au cours du vieillissement.Pour tester cette hypothèse, nous avons étudié l'AVC chez des souris jeunes et âgées avec ou sans déplétion antérieur des BAMs. Nos résultats ont montré que le déficit fonctionnel de l'AVC était aggravé chez les souris âgées déplétées en BAMs. Cette aggravation du résultat fonctionnel s'accompagnait (i) d'une augmentation de l'expression de la P-sélectine endothéliale, (ii) d'une augmentation du roulement et de l'adhésion des leucocytes à la paroi vasculaire, et (iii) d’une infiltration accrue de leucocytes dans l'hémisphère lésé. Ces réponses immunitaires exacerbées étaient présentes à la fois dans la phase aiguë et subaiguë après le début de l'AVC, suggérant ainsi que la présence de BAMs assure un contrôle à long terme de la réponse immunitaire après un AVC. En utilisant le séquençage ARN à partir de BAMs isolés, nous montrons que les BAMs modifient leur phénotype transcriptomique au cours du vieillissement pour surexprimer des gènes impliqués dans la régulation de la réponse immunitaire innée et adaptative et de la présentation des antigènes.Nos résultats montrent que les BAMs acquièrent au cours du vieillissement un rôle central dans l’orchestration de la réponse neuroinflammatoire déclenchées par un AVC, et que leur présence garantit une bonne régulation de la réponse immunitaire.

  • Central nervous system-associated macrophages modulate the immune response following stroke in aged mice

    by Damien Levard, Célia Seillier, Mathys Bellemain-Sagnard, Antoine Philippe Fournier, Eloïse Lemarchand, Chantal Dembech, Gaëtan Riou, Karina McDade, Colin Smith, Conor McQuaid, et al.

    Age is a major nonmodifiable risk factor for ischemic stroke. Central nervous system-associated macrophages (CAMs) are resident immune cells located along the brain vasculature at the interface between the blood circulation and the parenchyma. By using a clinically relevant thromboembolic stroke model in young and aged male mice and corresponding human tissue samples, we show that during aging, CAMs acquire a central role in orchestrating immune cell trafficking after stroke through the specific modulation of adhesion molecules by endothelial cells. The absence of CAMs provokes increased leukocyte infiltration (neutrophils and CD4+ and CD8+ T lymphocytes) and neurological dysfunction after stroke exclusively in aged mice. Major histocompatibility complex class II, overexpressed by CAMs during aging, plays a significant role in the modulation of immune responses to stroke. We demonstrate that during aging, CAMs become central coordinators of the neuroimmune response that ensure a long-term fine-tuning of the immune responses triggered by stroke.


  • Open Access

    Improving stroke outcomes in hyperglycemic mice by modulating tPA/NMDAR signaling to reduce inflammation and hemorrhages

    by Florent Lebrun, Damien Levard, Eloïse Lemarchand, Mervé Yetim, Jonathane Furon, Fanny Potzeha, Pauline Marie, Flavie Lesept, Manuel Blanc, Benoit Haelewyn, et al.

    The pharmacological intervention for ischemic stroke hinges on intravenous administration of the recombinant tissue-type plasminogen activator (rtPA, Alteplase/Actilyse) either as a standalone treatment or in conjunction with thrombectomy. However, despite its clinical significance, broader use of rtPA is constrained because of the risk of hemorrhagic transformations (HTs). Furthermore, the presence of diabetes or chronic hyperglycemia is associated with an elevated risk of HT subsequent to thrombolysis. This detrimental impact of tPA on the neurovascular unit in patients with hyperglycemia has been ascribed to its capacity to induce endothelial N-methyl-D-aspartate receptor (NMDAR) signaling, contributing to compromised blood-brain barrier integrity and neuroinflammatory processes. In a mouse model of thromboembolic stroke with chronic hyperglycemia, we assessed the effectiveness of rtPA and N-acetylcysteine (NAC) as thrombolytic agents. We also tested the effect of blocking tPA/NMDAR signaling using a monoclonal antibody, Glunomab. Magnetic resonance imaging, speckle contrast imaging, flow cytometry, and behavioral tasks were used to evaluate stroke outcomes. In hyperglycemic animals, treatment with rtPA resulted in lower recanalization rates and increased HTs. Conversely, NAC treatment reduced lesion sizes while mitigating HTs. After a single administration, either in standalone or combined with rtPA-induced thrombolysis, Glunomab reduced brain lesion volumes, HTs, and neuroinflammation after stroke, translating into improved neurological outcomes. Additionally, we demonstrated the therapeutic efficacy of Glunomab in combination with NAC or as a standalone strategy in chronic hyperglycemic animals. Counteracting tPA-dependent endothelial NMDAR signaling limits ischemic damages induced by both endogenous and exogenous tPA, including HTs and inflammatory processes after ischemic stroke in hyperglycemic animals.


  • Parabiosis Discriminates the Circulating, Endothelial, and Parenchymal Contributions of Endogenous Tissue-Type Plasminogen Activator to Stroke

    by Jonathane Furon, Florent Lebrun, Mervé Yétim, Damien Levard, Pauline Marie, Cyrille Orset, Sara Martinez de Lizarrondo, Denis Vivien, Carine Ali

    BACKGROUND: Intravenous injection of alteplase, a recombinant tPA (tissue-type plasminogen activator) as a thrombolytic agent has revolutionized ischemic stroke management. However, tPA is a more complex enzyme than expected, being for instance able to promote thrombolysis, but at the same time, also able to influence neuronal survival and to affect the integrity of the blood-brain barrier. Accordingly, the respective impact of endogenous tPA expressed/present in the brain parenchyma versus in the circulation during stroke remains debated. METHODS: To address this issue, we used mice with constitutive deletion of tPA (tPA Null [tPA-deficient mice]) or conditional deletion of endothelial tPA (VECad [vascular endothelial-Cadherin-Cre-recombinase]-Cre ∆tPA ). We also developed parabioses between tPA Null and wild-type mice (tPA WT ), anticipating that a tPA WT donor would restore levels of tPA to normal ones, in the circulation but not in the brain parenchyma of a tPA Null recipient. Stroke outcomes were investigated by magnetic resonance imaging in a thrombo-embolic or a thrombotic stroke model, induced by local thrombin injection or FeCl 3 application on the endothelium, respectively. RESULTS: First, our data show that endothelial tPA, released into the circulation after stroke onset, plays an overall beneficial role following thrombo-embolic stroke. Accordingly, after 24 hours, tPA Null /tPA Null parabionts displayed less spontaneous recanalization and reperfusion and larger infarcts compared with tPA WT /tPA WT littermates. However, when associated to tPA WT littermates, tPA Null mice had similar perfusion deficits, but less severe brain infarcts. In the thrombotic stroke model, homo- and hetero-typic parabionts did not differ in the extent of brain damages and did not differentially recanalize and reperfuse. CONCLUSIONS: Together, our data reveal that during thromboembolic stroke, endogenous circulating tPA from endothelial cells sustains a spontaneous recanalization and reperfusion of the tissue, thus, limiting the extension of ischemic lesions. In this context, the impact of endogenous parenchymal tPA is limited.


  • Persistent neuroinflammation and behavioural deficits after single mild traumatic brain injury

    by Antoine Drieu, Anastasia Lanquetin, Paul Prunotto, Zuhal Gulhan, Swannie Pédron, Gloria Vegliante, Daniele Tolomeo, Sophie Serrière, Johnny Vercouillie, Laurent Galineau, et al.

    Despite an apparently silent imaging, some patients with mild traumatic brain injury (TBI) experience cognitive dysfunctions, which may persist chronically. Brain changes responsible for these dysfunctions are unclear and commonly overlooked. It is thus crucial to increase our understanding of the mechanisms linking the initial event to the functional deficits, and to provide objective evidence of brain tissue alterations underpinning these deficits. We first set up a murine model of closed-head controlled cortical impact, which provoked persistent cognitive and sensorimotor deficits, despite no evidence of brain contusion or bleeding on MRI, thus recapitulating features of mild TBI. Molecular MRI for P-selectin, a key adhesion molecule, detected no sign of cerebrovascular inflammation after mild TBI, as confirmed by immunostainings. By contrast, in vivo PET imaging with the TSPO ligand [18F]DPA-714 demonstrated persisting signs of neuroinflammation in the ipsilateral cortex and hippocampus after mild TBI. Interestingly, immunohistochemical analyses confirmed these spatio-temporal profiles, showing a robust parenchymal astrogliosis and microgliosis, at least up to 3 weeks post-injury in both the cortex and hippocampus. In conclusion, we show that even one single mild TBI induces long-term behavioural deficits, associated with a persistent neuro-inflammatory status that can be detected by PET imaging.


  • Factor XII protects neurons from apoptosis by epidermal and hepatocyte growth factor receptor‐dependent mechanisms

    by Eugénie Garnier, Damien Levard, Carine Ali, Izaskun Buendia, Yannick Hommet, Maxime Gauberti, Tiziana Crepaldi, Paolo Comoglio, Marina Rubio, Denis Vivien, et al.


  • Alcohol exposure–induced neurovascular inflammatory priming impacts ischemic stroke and is linked with brain perivascular macrophages

    by Antoine Drieu, Anastasia Lanquetin, Damien Levard, Martina Glavan, Francisco Campos, Aurélien Quenault, Eloïse Lemarchand, Mikaël Naveau, Anne Lise Pitel, José Castillo, et al.

    Alcohol abuse is a major public health problem worldwide, causing a wide range of preventable morbidity and mortality. In this translational study, we show that heavy drinking (HD) (≥6 standard drinks/day) is independently associated with a worse outcome for ischemic stroke patients. To study the underlying mechanisms of this deleterious effect of HD, we performed an extensive analysis of the brain inflammatory responses of mice chronically exposed or not to 10% alcohol before and after ischemic stroke. Inflammatory responses were analyzed at the parenchymal, perivascular, and vascular levels by using transcriptomic, immunohistochemical, in vivo 2-photon microscopy and molecular MRI analyses. Alcohol-exposed mice show, in the absence of any other insult, a neurovascular inflammatory priming (i.e., an abnormal inflammatory status including an increase in brain perivascular macrophages [PVM]) associated with exacerbated inflammatory responses after a secondary insult (ischemic stroke or LPS challenge). Similar to our clinical data, alcohol-exposed mice showed larger ischemic lesions. We show here that PVM are key players on this aggravating effect of alcohol, since their specific depletion blocks the alcohol-induced aggravation of ischemic lesions. This study opens potentially new therapeutic avenues aiming at blocking alcohol-induced exacerbation of the neurovascular inflammatory responses triggered after ischemic stroke.


  • Immune Responses and Anti-inflammatory Strategies in a Clinically Relevant Model of Thromboembolic Ischemic Stroke with Reperfusion

    by Antoine Drieu, Izaskun Buendia, Damien Levard, Pauline Hélie, Camille Brodin, Denis Vivien, Marina Rubio

    The poor clinical relevance of experimental models of stroke contributes to the translational failure between preclinical and clinical studies testing anti-inflammatory molecules for ischemic stroke. Here, we (i) describe the time course of inflammatory responses triggered by a thromboembolic model of ischemic stroke and (ii) we examine the efficacy of two clinically tested anti-inflammatory drugs: Minocycline or anti-CD49d antibodies (tested in stroke patients as Natalizumab) administered early (1 h) or late (48 h) after stroke onset. Radiological (lesion volume) and neurological (grip test) outcomes were evaluated at 24 h and 5 days after stroke. Immune cell responses peaked 48 h after stroke onset. Myeloid cells (microglia/macrophages, dendritic cells, and neutrophils) were already increased 24 h after stroke onset, peaked at 48 h, and remained increased—although to a lesser extent—5 days after stroke onset. CD8+ and CD4+ T-lymphocytes infiltrated the ipsilateral hemisphere later on (only from 48 h). These responses occurred together with a progressive blood-brain barrier leakage at the lesion site, starting 24 h after stroke onset. Lesion volume was maximal 24–48 h after stroke onset. Minocycline reduced both lesion volume and neurological deficit only when administered early after stroke onset. The blockade of leukocyte infiltration by anti-CD49d had no impact on lesion volume or long-term neurological deficit, independently of the timing of treatment. Our data are in accordance with the results of previous clinical reports on the use of Minocycline and Natalizumab on ischemic stroke. We thus propose the use of this clinically relevant model of thromboembolic stroke with recanalization for future testing of anti-inflammatory strategies for stroke.


  • Open Access

    Anti-inflammatory treatments for stroke: from bench to bedside

    by Antoine Drieu, Damien Levard, Denis Vivien, Marina Rubio

    So far, intravenous tissue-type plasminogen activator (tPA) and mechanical removal of arterial blood clot (thrombectomy) are the only available treatments for acute ischemic stroke. However, the short therapeutic window and the lack of specialized stroke unit care make the overall availability of both treatments limited. Additional agents to combine with tPA administration or thrombectomy to enhance efficacy and improve outcomes associated with stroke are needed. Stroke-induced inflammatory processes are a response to the tissue damage due to the absence of blood supply but have been proposed also as key contributors to all the stages of the ischemic stroke pathophysiology. Despite promising results in experimental studies, inflammation-modulating treatments have not yet been translated successfully into the clinical setting. This review will (a) describe the timing of the stroke immune pathophysiology; (b) detail the immune responses to stroke sift-through cell type; and (c) discuss the pitfalls on the translation from experimental studies to clinical trials testing the therapeutic pertinence of immune modulators.